Hospital
Southside Community Hospital, INC.
Southside Community Hospital, INC. was paid $26.64M by Medicaid between Jan 2018 and Dec 2024, across 250 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 16% of everything it billed.
33Billing provider infoSOUTHSIDE COMMUNITY HOSPITAL, INC.
FARMVILLE, VA 23901
FARMVILLE, VA 23901
33aNPI1518952761assigned 09/14/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$26.64M
24GClaims749,048
24DCodes billed250
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#26 of 80
Median peer was paid$14.69M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 88,884 | $2.00M | |
| 2019 | 120,100 | $3.02M | |
| 2020 | 102,146 | $3.62M | |
| 2021 | 120,839 | $4.26M | |
| 2022 | 113,735 | $4.37M | |
| 2023 | 119,926 | $5.23M | |
| 2024incomplete | 83,418 | $4.14M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 16% | 15,379 | 12,056 | $4.37M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 28,006 | 23,658 | $4.22M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 27,336 | 22,819 | $3.95M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 26,963 | 23,518 | $3.87M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.1% | 6,238 | 5,479 | $1.35M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 5,843 | 4,999 | $765K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.6% | 7,782 | 6,002 | $696K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.4% | 11,326 | 10,442 | $629K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 3,963 | 3,600 | $541K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.7% | 4,223 | 3,640 | $448K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.5% | 2,487 | 1,764 | $390K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 2,294 | 1,956 | $386K |
238 more codes
| G0378 | Hospital observation service, per hour | 1.3% | 2,619 | $359K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.2% | 1,579 | $331K |
| 59025 | Fetal non-stress test | 1.1% | 1,499 | $289K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 6,642 | $283K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,172 | $245K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,599 | $209K |
| 80053 | Comprehensive metabolic panel | <1% | 36,880 | $203K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 568 | $192K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 393 | $191K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,932 | $169K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,476 | $154K |
| 36415 | Collection of venous blood by venipuncture | <1% | 13,703 | $151K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,213 | $135K |
| 93971 | <1% | 1,519 | $119K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 442 | $95K |
| 70496 | <1% | 422 | $88K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,062 | $84K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 647 | $84K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 481 | $82K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 639 | $81K |
| 71250 | <1% | 1,190 | $73K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,118 | $69K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 42,071 | $63K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 611 | $61K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,014 | $54K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 1,635 | $53K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 13,832 | $49K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,267 | $43K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,039 | $41K |
| 83880 | <1% | 5,441 | $41K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 110 | $37K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 181 | $37K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 692 | $36K |
| 76801 | <1% | 825 | $36K | |
| 71271 | <1% | 334 | $35K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,938 | $32K |
| 71045 | Radiologic examination, chest; single view | <1% | 13,694 | $31K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 56 | $29K |
| 74018 | <1% | 1,439 | $28K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 29 | $22K |
| 80329 | <1% | 2,028 | $20K | |
| 73564 | <1% | 2,367 | $20K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,650 | $20K |
| 87040 | <1% | 3,243 | $20K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,226 | $20K |
| 90715 | <1% | 1,179 | $18K | |
| 73610 | <1% | 1,922 | $18K | |
| 93017 | <1% | 150 | $18K | |
| 29125 | <1% | 128 | $17K | |
| 76641 | <1% | 105 | $16K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 67 | $16K |
| 84484 | <1% | 17,018 | $16K | |
| 73630 | <1% | 1,905 | $14K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 95 | $13K |
| 85380 | <1% | 3,071 | $13K | |
| 93000 | <1% | 5,808 | $12K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 14,824 | $11K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,287 | $11K |
| 73030 | <1% | 1,595 | $11K | |
| 70498 | <1% | 379 | $11K | |
| 81001 | <1% | 28,156 | $11K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 66 | $10K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,239 | $10K |
| 80320 | <1% | 2,387 | $9K | |
| 72100 | <1% | 1,077 | $9K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 25 | $9K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 18,477 | $9K |
| 77066 | Tomosynthesis, mammo | <1% | 220 | $8K |
| 76770 | <1% | 104 | $8K | |
| 76830 | Ultrasound, transvaginal | <1% | 87 | $8K |
| 76642 | <1% | 69 | $8K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 16,574 | $7K |
| 73130 | <1% | 1,217 | $7K | |
| 86900 | <1% | 2,148 | $7K | |
| J3490 | Unclassified drugs | <1% | 8,029 | $7K |
| 12001 | <1% | 29 | $6K | |
| 80047 | <1% | 1,020 | $6K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,274 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,774 | $6K |
| 73502 | <1% | 552 | $5K | |
| 83605 | <1% | 7,012 | $5K | |
| 73110 | <1% | 561 | $5K | |
| 87081 | <1% | 5,949 | $5K | |
| 82962 | <1% | 9,504 | $4K | |
| 96367 | <1% | 1,837 | $4K | |
| 85027 | <1% | 8,982 | $4K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 138 | $4K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 28 | $4K |
| 82565 | <1% | 1,197 | $4K | |
| 93970 | <1% | 28 | $3K | |
| 80361 | <1% | 156 | $3K | |
| 94726 | <1% | 95 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,028 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 7,604 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,894 | $3K |
| 74021 | <1% | 77 | $3K | |
| 99070 | <1% | 1,212 | $3K | |
| 85610 | <1% | 7,437 | $3K | |
| 83690 | <1% | 12,408 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,555 | $2K |
| 93976 | <1% | 99 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,819 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,490 | $2K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 79 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,924 | $2K |
| 76536 | <1% | 28 | $2K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 299 | $2K |
| 80061 | Lipid panel | <1% | 439 | $2K |
| 81025 | <1% | 2,176 | $2K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 100 | $2K |
| 93246 | <1% | 30 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,495 | $2K |
| Q3014 | Telehealth originating site facility fee | <1% | 434 | $2K |
| 73140 | <1% | 190 | $2K | |
| 96376 | <1% | 4,147 | $2K | |
| 83735 | <1% | 9,236 | $1K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 19 | $1K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 50 | $1K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 13 | $1K |
| 87186 | <1% | 2,162 | $1K | |
| 82803 | <1% | 3,145 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 486 | $1K |
| 73590 | <1% | 150 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,450 | $1K |
| 77065 | Tomosynthesis, mammo | <1% | 42 | $1K |
| 72131 | <1% | 25 | $1K | |
| 94729 | <1% | 60 | $958.86 | |
| 0012A | <1% | 43 | $933.53 | |
| 86850 | <1% | 1,617 | $899.81 | |
| 94664 | <1% | 513 | $880.15 | |
| 86901 | <1% | 2,142 | $869.90 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,595 | $860.09 |
| 96523 | <1% | 16 | $857.94 | |
| 90686 | <1% | 55 | $839.89 | |
| 87210 | <1% | 2,113 | $810.67 | |
| 80069 | <1% | 473 | $780.83 | |
| 84702 | <1% | 2,273 | $776.29 | |
| 0011A | <1% | 42 | $729.06 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 772 | $658.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,621 | $634.21 |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 478 | $610.52 |
| 85014 | <1% | 1,228 | $536.88 | |
| 82550 | <1% | 1,503 | $455.87 | |
| 85730 | <1% | 2,305 | $422.71 | |
| 36600 | <1% | 230 | $418.64 | |
| 73080 | <1% | 48 | $392.66 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,087 | $366.48 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,322 | $347.69 |
| 84703 | <1% | 750 | $339.62 | |
| 87807 | <1% | 1,027 | $314.61 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,654 | $314.31 |
| 84145 | <1% | 319 | $301.12 | |
| 81003 | <1% | 1,210 | $295.71 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,365 | $280.21 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,521 | $271.61 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,068 | $224.64 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 65 | $207.86 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,129 | $193.11 |
| 85007 | <1% | 145 | $169.74 | |
| 96368 | <1% | 44 | $167.55 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,731 | $163.14 |
| 72170 | <1% | 60 | $152.46 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,647 | $150.58 |
| 87147 | <1% | 1,537 | $148.93 | |
| 70486 | <1% | 25 | $146.98 | |
| 84100 | <1% | 989 | $142.51 | |
| 51702 | <1% | 26 | $134.28 | |
| 87088 | <1% | 1,120 | $119.59 | |
| 85651 | <1% | 706 | $112.69 | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,757 | $111.19 |
| 87077 | <1% | 1,057 | $98.62 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,546 | $95.39 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,276 | $93.80 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,340 | $93.70 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,152 | $92.89 |
| G0008 | Administration of influenza virus vaccine | <1% | 16 | $90.56 |
| 86140 | <1% | 440 | $85.39 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 182 | $83.90 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,020 | $79.95 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 17 | $78.89 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 797 | $78.16 |
| S0028 | Injection, famotidine, 20 mg | <1% | 33 | $78.12 |
| 80076 | <1% | 29 | $75.51 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 241 | $74.58 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 56 | $74.15 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,228 | $73.68 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 945 | $65.09 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 25 | $63.76 |
| 73090 | <1% | 31 | $61.48 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 707 | $57.64 |
| 84132 | <1% | 397 | $54.27 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 614 | $51.06 |
| 82330 | <1% | 91 | $36.72 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 295 | $36.15 |
| 85018 | <1% | 93 | $35.28 | |
| 82947 | <1% | 147 | $33.34 | |
| 94760 | <1% | 1,941 | $32.34 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 334 | $32.07 |
| 87070 | <1% | 181 | $25.89 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 41 | $22.12 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 2,271 | $22.02 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 562 | $18.13 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 528 | $16.63 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 417 | $14.99 |
| 85652 | <1% | 196 | $14.97 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 151 | $14.65 |
| 87205 | <1% | 172 | $12.93 | |
| 82728 | <1% | 26 | $12.68 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 514 | $12.41 |
| J2704 | Injection, propofol, 10 mg | <1% | 5,050 | $11.69 |
| 87184 | <1% | 331 | $8.78 | |
| 84295 | <1% | 92 | $8.19 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 100 | $5.89 |
| 83615 | <1% | 20 | $5.39 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 294 | $2.60 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 40 | $2.60 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 16 | $2.36 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 17 | $1.67 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 15 | $0.00 |
| J7799 | Noc drugs, other than inhalation drugs, administered through dme | 0% | 69 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 261 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 31 | $0.00 |
| G1011 | Clinical decision support mechanism, qualified tool not otherwise specified, as defined by the medicare appropriate use criteria program | 0% | 15 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 53 | $0.00 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 34 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 12 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 15 | $0.00 |
| 99292 | 0% | 12 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 570 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 261 | $0.00 |
| 80179 | 0% | 114 | $0.00 | |
| 84439 | 0% | 49 | $0.00 | |
| 80143 | 0% | 113 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 151 | $0.00 |
| 82272 | 0% | 16 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 60 | $0.00 |
| 84550 | 0% | 40 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAVENPORT, DOUG (CFO)
| Provider | Location | Paid |
|---|---|---|
| Healtheast Care System | Saint Paul, MN | $3.53M |
| Healtheast Outpatient Services, LLC | Saint Paul, MN | $1.44M |
| Bedford Memorial Hospital | Bedford, VA | $517K |
| Southside Community Hospital INC. | Farmville, VA | $361K |
| Southside Community Hospital, INC. | Farmville, VA | $19K |
| Centra Pace - Farmville | Farmville, VA | $16K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.